Medical device giant Johnson & Johnson (J&J) has launched two new products in Europe, the Middle East and Africa - the Ethizia haemostatic sealing patch, and the Cereglide aspiration catheter. 

Ethizia, a pad designed to control bleeding on internal organs except neurological and cardiovascular, gained CE mark approval in November 2023. The patch, developed by J&J medtech company Ethicon, features synthetic polymer technology, and claims to be the first and only haemostatic matrix that is equally productive and active on both sides. 

The haemostatic sealing patch stopped bleeding in 30 seconds in 80% of the patients who were examined in a clinical trial. It stopped bleeding six times faster than the leading Fibrin sealing patch, according to J&J in the 18 April announcement. 

This launch comes after Ethicon acquired Netherlands-based GATT Technologies in May 2022, which utilises differentiated synthetic polymers to develop haemostatic and sealant products for solving complex surgical bleeding and leak challenges. 

In 2021, Ethicon acquired Takeda Pharmaceutical’s TachoSil Fibrin Sealant Patch in a $400m deal. The patch is indicated for use with manual compression as an adjunct to haemostasis in cardiovascular and hepatic surgery. 

J&J medtech company Cerenovus has launched the Cereglide aspiration catheter in Europe, adding to its stroke solutions portfolio that includes a revascularisation device and clot extractor. 

Aspiration catheters are used to remove blood clots or debris from blood vessels. They are used in treating ischemic strokes, where a clot blocks blood flow to the brain. They suction out the blockage, restoring blood flow and preventing further damage. According to a report on GlobalData’s Medical Intelligence Center, the number of aspiration catheter procedures undertaken will be 58,475 in the US in 2030, growing from 24,503 in 2023. 

In the announcement accompanying the launch, president of Cerenovus Mark Dickinson said: “With CEREGLIDE 71 Aspiration Catheter, we can now access occlusion sites and aspirate clots more rapidly and efficiently, maintaining a smooth interaction with stent retrievers when used in co-aspiration.  

“This leads to the prompt restoration of blood flow in the patient's brain, which has the potential to save more lives and improve long-term clinical outcomes.”